Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells

Blood

Volumn 112, Issue 8, 2008, Pages 3205-3216

  Chen, Changyi ^a   Chai, Hong ^a   Wang, Xinwen ^a   Jiang, Jun ^a   Jamaluddin, Md Sana ^a   Liao, Dan ^a   Zhang, Yuqing ^a   Wang, Hao ^a   Bharadwaj, Uddalak ^a   Zhang, Sheng ^a   Li, Min ^a   Lin, Peter ^a   Yao, Qizhi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CATALASE; CD40 ANTIGEN; CD40 LIGAND; ENDOTHELIAL NITRIC OXIDE SYNTHASE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MICRORNA; MITOCHONDRIAL COMPLEX 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; OXIDOREDUCTASE; OXYGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SELENOMETHIONINE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANION;

3' UNTRANSLATED REGION; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; ATHEROSCLEROSIS; CELL LEVEL; CELL NUCLEUS; CONTROLLED STUDY; CORONARY ARTERY; CYTOPLASM; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN TRANSPORT; RNA BINDING; RNA STABILITY; SIGNAL TRANSDUCTION; SWINE; VASODILATATION; ANIMAL; BIOLOGICAL MODEL; CORONARY BLOOD VESSEL; CYTOLOGY; DOMINANT GENE; METABOLISM; PHOSPHORYLATION; VASCULAR ENDOTHELIUM;

ANIMALS; ANIONS; CD40 LIGAND; CORONARY VESSELS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GENES, DOMINANT; HUMANS; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; NITRIC OXIDE SYNTHASE TYPE III; OXYGEN; PHOSPHORYLATION; SUPEROXIDES; SWINE;

EID: 54049156519     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-143479     Document Type: Article

References (53)

1. Landmesser U, Hornig B. Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation. 2004;109:1127-1133.
2. Lutgens E, Daemen MJ. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med. 2002;12:27-32.
3. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002:106:896-899.
4. Grewal IS, Flavell RA. The CD40 ligand: at the center of the immune universe? Immunol Res. 1997;16:59-70.
5. Koutroubakis IE. Theodoropoulou A. Xidakis C. et al. Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2004:16:1147-1152.
6. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003:348:1104-1111.
7. Thienel U, Loike J, Yellin MJ. CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets. Cell Immunol. 1999;198:87-95.
8. Déchanet J, Grosset C, Taupin JL, et al. CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J Immunol. 1997;159:5640-5647.
9. Chakrabarti S, Blair P Freedman JE. CD40-40L signaling in vascular inflammation. J Biol Chem. 2007;282:18307-18317.
10. Mach F, Schonbeck U, Fabunmi RP, et al. Tlymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am J Pathol. 1999;154:229-238.
11. Miller DL Yaron R, Yellin MJ. CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J Leukoc Biol. 1998;63:373-379.
12. Flaxenburg JA, Melter M. Lapchak PH, Briscoe DM. Pal S. The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase. J Immunol. 2004;172:7503-7509.
13. Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation. 2002;106: 981-986.
14. Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K. Freedman JE. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol. 2005;25:2428-2434.
15. Sanguigni V, Ferro D, Pignatelli P, et al. CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia. J Am Coll Cardiol. 2005:45:35-42.
16. Mach F Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature. 1998:394: 200-203.
17. Lai PF Mohamed F Monge JC, Stewart DJ. Downregulation of eNOS mRNA expression by TNF-α: identification and functional characterization of RNA-protein interactions in the 3'UTR. Cardiovasc Res. 2003:59:160-168.
18. Alonso J, Sánchez de Miguel L, Montón M, Casado S, López-Farré A. Endothelial cytosolic proteins bind to the 3' untranslated region of endothelial nitric oxide synthase mRNA: regulation by tumor necrosis factor alpha. Mol Cell Biol. 1997:17:5719-5726.
19. Searles CD, Miwa Y Harrison DG, Ramasamy S. Posttranscriptional regulation of endothelial nitric oxide synthase during cell growth. Circ Res. 1999:85:588-595.
20. Suárez Y, Fernández-Hernando C, Pober JS, Sessa WC. Dicer dependent micro RNAs regulate gene expression and functions in human endothelial cells. Circ Res. 2007:100:1164-1173.
21. Sanger Institute. miRBase Targets. http://microrna. sanger.ac.uk/targets/ v5. Accessed June 4, 2008.
22. Whitehead Institute for Biomedical Research. Target Scan. http://www.targetscan.org. Accessed June 4, 2008.
23. Kojima H, Urano Y, Kikuchi K, Higuchi T Hirata Y, Nagano T Fluorescent indicators for imaging nitric oxide production. Angew Chem Int Ed Engl. 1999;38:3209-3212.
24. Kimura K, Tsuda H, Kwangseok Y, Tamura N, Kanai Y, Kobayashi S. Study of plasma levels of soluble CD40 ligand in systemic lupus erythematosus patients who have undergone plasmapheresis. Ther Apher Dial. 2005:9:64-68.
25. Genova ML, Pich MM, Bernacchia A, et al. The mitochondrial production of reactive oxygen species in relation to aging and pathology. Ann N Y Acad Sci. 2004;1011:86-100.
26. Madamanchi NR, Hakim ZS, Runge MS. Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes. J Thromb Haemost. 2005;3: 254-267.
27. Matés JM, Sanchez-Jimenez F. Antioxidant enzymes and their implications in pathophysiologic processes. Front Biosci. 1999;4:D339-D345.
28. Chai H, Yang H. Yan S. et al. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. J Acquir Immune Defic Syndr. 2005;40:12-19.
29. Monaco C, Paleolog E. Nuclear factor κB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res. 2004;61:671-682.
30. National Center for Biotechnology Information. GenBank. http://www.ncbi.nlm.nih.gov/Genbank/. Accessed June 10, 2008.
31. Wienhold D, Berger N, Armengol E, Büttner M, Saalmüller A, Pfaff E. Gloning, sequencing and expression of porcine CD40 ligand in Escherichia coli and human and porcine cells. Cytokine. 2002:20:274-282.
32. Choi I. Kim SD, Cho B. et al. Xenogeneic interaction between human CD40L and porcine CD40 activates porcine endothelial cells through NF-kappa B signaling. Mol Immunol. 2008;45:575-580.
33. Fleming I, Bauersachs J. Fisslthaler B. Busse R. Ca2+-independent activation of the endothelial nitric oxide synthase in response to tyrosine phosphatase inhibitors and fluid shear stress. Circ Res. 1998;82:686-695.
34. Kawashima S, Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vase Biol. 2004;24:998-1005.
35. SessaWC.eNOS at a glance. J Cell Sci. 2004; 117:2427-2429.
36. Chai H. Yan S, Wang H, et al. CD40 ligand increases expression of its receptor CD40 in human coronary artery endothelial cells. Surgery. 2006;140:236-242.
37. Schäfer A, Alp NJ, Cai S, et al. Reduced vascular NO bioavailability in diabetes increases platelet activation in vivo. Arterioscler Thromb Vasc Biol. 2004;24:1720-1726.
38. Wassmann S, Wassmann K. Nickenig G. Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension. 2004;44:381-386.
39. Azumi H, Inoue N, Ohashi Y. et al. Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris: important role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol. 2002;22:1838-1844.
40. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997:100:2153-2157.
41. Barry-Lane PA. Patterson C, van derMerwe M, et al. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest. 2001; 108:1513-1522.
42. Cyrus T, Witztum JL, Rader DJ, et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest. 1999;103:1597-1604.
43. Brandes RP, Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. Gardiovasc Res. 2005;65:16-27.
44. Nordberg J, Arner ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med. 2001;31:1287-1312.
45. Allan CB, Lacourciere GM, Stadtman TC. Responsiveness of selenoproteins to dietary selenium. Annu Rev Nutr. 1999;19:1-16.
46. Safaya R, Chai H, Kougias P, et al. Effect of lysophosphatidylcholine on vasomotor functions of porcine coronary arteries. J Surg Res. 2005;126: 182-188.
47. Hu Y, Dietrich H, Metzler B, Wick G, Xu Q. Hyperexpression and activation of extracellular signalregulated kinases (ERK1/2) in atherosclerotic lesions of cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol. 2000;20:18-26.
48. Vara N, de Lemos JA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003;108:1049-1052.
49. Garlichs CD, John S, Schmeiber A, et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation. 2001;104:2395-2400.
50. Semb AG, van Wissen S, Ueland T, et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol. 2003;41:275-279.
51. Damås JK, Otterdal K, Yndestad A, et al. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation. 2004:110:999-1005.
52. Häkkinen T, Karkola K, Ylä-Herttuala S. Macrophages, smooth muscle cells, endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions: colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD16(Fc gammaRIII). Virchows Arch. 2000; 437:396-405.
53. Mulhaupt F, Matter CM, Kwak BR, et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res. 2003;59:755-766.